SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biodoc who wrote (6592)5/10/1999 6:38:00 PM
From: Cacaito   of 7041
 
It is a population enriched by the responders on both the treatment and placebo group when the trial became open.

Many opted out, and many did not responded.

The leftover were the responders with mild disease (pre-screned) and low side effects (pre-screenend and re-screened).

These is my view after following many of the reports from the company, which were surprisingly honest during one the major Urology meetings last year in California.

FDA will not buy that. Neither this year, neither next. Ergo is the model.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News